122 related articles for article (PubMed ID: 18691764)
1. Use of the rabbit with a failing heart to test for torsadogenicity.
Hamlin RL; Kijtawornrat A
Pharmacol Ther; 2008 Aug; 119(2):179-85. PubMed ID: 18691764
[TBL] [Abstract][Full Text] [Related]
2. The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes.
Carlsson L
Pharmacol Ther; 2008 Aug; 119(2):160-7. PubMed ID: 18558435
[TBL] [Abstract][Full Text] [Related]
3. Preclinical assessment of drug-induced proarrhythmias: role of the arterially perfused rabbit left ventricular wedge preparation.
Wang D; Patel C; Cui C; Yan GX
Pharmacol Ther; 2008 Aug; 119(2):141-51. PubMed ID: 18423604
[TBL] [Abstract][Full Text] [Related]
4. Torsades de pointes liability inter-model comparisons: the experience of the QT PRODACT initiative.
Hashimoto K
Pharmacol Ther; 2008 Aug; 119(2):195-8. PubMed ID: 18486227
[TBL] [Abstract][Full Text] [Related]
5. Apamin induces early afterdepolarizations and torsades de pointes ventricular arrhythmia from failing rabbit ventricles exhibiting secondary rises in intracellular calcium.
Chang PC; Hsieh YC; Hsueh CH; Weiss JN; Lin SF; Chen PS
Heart Rhythm; 2013 Oct; 10(10):1516-24. PubMed ID: 23835258
[TBL] [Abstract][Full Text] [Related]
6. Assessment of QT-prolonging drugs in the isolated normal and failing rabbit hearts.
Kijtawornrat A; Sawangkoon S; Hamlin RL
J Toxicol Sci; 2012; 37(3):455-62. PubMed ID: 22687985
[TBL] [Abstract][Full Text] [Related]
7. Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability.
Pugsley MK; Hancox JC; Curtis MJ
Pharmacol Ther; 2008 Aug; 119(2):115-7. PubMed ID: 18590766
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk.
Gintant GA
Pharmacol Ther; 2008 Aug; 119(2):199-209. PubMed ID: 18621077
[TBL] [Abstract][Full Text] [Related]
9. Uni- or bi-ventricular hypertrophy and susceptibility to drug-induced torsades de pointes.
Panyasing Y; Kijtawornrat A; Del Rio C; Carnes C; Hamlin RL
J Pharmacol Toxicol Methods; 2010; 62(2):148-56. PubMed ID: 20435152
[TBL] [Abstract][Full Text] [Related]
10. The canine model with chronic, complete atrio-ventricular block.
Oros A; Beekman JD; Vos MA
Pharmacol Ther; 2008 Aug; 119(2):168-78. PubMed ID: 18514320
[TBL] [Abstract][Full Text] [Related]
11. Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias.
Thomsen MB; Matz J; Volders PG; Vos MA
Pharmacol Ther; 2006 Oct; 112(1):150-70. PubMed ID: 16714061
[TBL] [Abstract][Full Text] [Related]
12. Use of a failing rabbit heart as a model to predict torsadogenicity.
Kijtawornrat A; Nishijima Y; Roche BM; Keene BW; Hamlin RL
Toxicol Sci; 2006 Sep; 93(1):205-12. PubMed ID: 16740615
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo models for testing arrhythmogenesis in drugs.
Carlsson L
J Intern Med; 2006 Jan; 259(1):70-80. PubMed ID: 16336515
[TBL] [Abstract][Full Text] [Related]
14. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
[TBL] [Abstract][Full Text] [Related]
15. An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts.
Wu L; Shryock JC; Song Y; Belardinelli L
J Pharmacol Exp Ther; 2006 Feb; 316(2):718-26. PubMed ID: 16234410
[TBL] [Abstract][Full Text] [Related]
16. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
Lin YL; Kung MF
Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):235-9. PubMed ID: 19145580
[TBL] [Abstract][Full Text] [Related]
17. QT prolongation in guinea pigs for preliminary screening of torsadogenicity of drugs and drug-candidates. II.
Testai L; Breschi MC; Martinotti E; Calderone V
J Appl Toxicol; 2007; 27(3):270-5. PubMed ID: 17265420
[TBL] [Abstract][Full Text] [Related]
18. Drugs for men and women - how important is gender as a risk factor for TdP?
Coker SJ
Pharmacol Ther; 2008 Aug; 119(2):186-94. PubMed ID: 18472167
[TBL] [Abstract][Full Text] [Related]
19. Early clinical development: evaluation of drug-induced torsades de pointes risk.
Vik T; Pollard C; Sager P
Pharmacol Ther; 2008 Aug; 119(2):210-4. PubMed ID: 18601950
[TBL] [Abstract][Full Text] [Related]
20. Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts.
Sugiyama A
Br J Pharmacol; 2008 Aug; 154(7):1528-37. PubMed ID: 18552873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
